Have you noticed that despite consuming leafy greens, nuts, and berries, our body still lacks the perfect amount of nutrients and minerals? Additionally, due to the change in the methodology of food cultivation, we are in deficit because of the chemicals being added to the soil and the depletion of natural minerals because of over-farming.
Therefore, food supplements have become the need of an hour. Performing physiological roles beyond the provision of simple nutrients, food supplements ensure a measurable amount of nutrition and make up for the poor food. Comprehending these issues of preventing nutritional deficiencies, many players in the market are providing supplements to increase energy, maintain strength and enhance performance.
One such organization, ZyCal Bioceuticals Healthcare Co Inc—with its unique ingredient Cyplexinol® provides an all-natural stem-cell activating growth-factor complex for new bone and cartilage tissue growth, forging a breakthrough in cellular and molecular nutrition.
ZyCal’s President and CEO, James J. Scaffidi, is backed by experts in medicines and surgery and is setting new standards in natural medicines and nutritional health. Under his leadership, the organization constantly conducts clinical trials and pre-clinical research and provides the industry with cutting-edge research and information on stem-cell activations and tissue regeneration.
The Prologue
ZyCal Bioceuticals Healthcare Co Inc. is the leader in nutritional osteoinductive growth-factor technology, hyper-focused on bone and joint health. ZyCal manufactures the only all-natural stem-cell activating growth-factor complex for new bone and cartilage tissue growth, forging a cellular and molecular nutrition breakthrough.
ZyCal is focused on bone and joint health, manufacturing, and marketing Cyplexinol® – the only orally administered all-natural growth-factor complex scientifically proven to turn on stem cells to grow new bone and cartilage tissue.
Cyplexinol® is a Bone Morphogenetic Protein (BMP) complex, which is a unique class of growth factors. This class is supported by over 50 years of research, 30 years of clinical and surgical usage, and nearly 15 years as an oral supplement usage and over 29,000 peer-reviewed studies and clinical trials.
ZyCal’s passion and commitment to the pinnacle in bone and joint health does not stop there, as the company has conducted and published multiple clinical trials and cases studies, including a university-level study, and is set to launch two large-scale trials with a Contract Research Organization (CRO), typically reserved for pharmaceutical products.
A True Expert
ZyCal was founded by James J. Scaffidi, its current President, and CEO. Mr Scaffidi has a degree in Biochemistry from the City University of New York, completing three years of graduate-level work in enzymology and protein purification. He is currently pursuing his doctorate in natural medicine.
Mr Scaffidi has spent 30 years in sales, marketing, management, and training in pharmaceuticals and diagnostic and surgical companies and has developed and led several clinical trials. ZyCal Bioceuticals Healthcare Company represents the culmination of his experience supported by past executives from such prestigious companies as P&G, J&J, and Unilever.
Mr Scaffidi was the brand manager at a surgical company manufacturing a surgical BMP-complex for spinal fusion. He saw the value of developing the only oral version of that complex for superior bone and joint health.
Mr Scaffidi launched his vision in 2006, bringing aboard experts and specialists from the surgical business to provide the ultimate in manufacturing expertise to create Cyplexinol® – the world’s only orally available stem-cell activating growth-factor complex to grow new bone and cartilage tissue.
Providing Unique Solutions
Mr Scaffidi elaborates on Cyplexinol® that the organization offers. It is a unique ingredient because it completely supports bone and joint health, unlike traditional supplements. Traditional bone supplements are primarily calcium, minerals, and vitamin mixtures that are designed to bind to bone tissue and help strengthen the tissue.
Cyplexinol® works by providing the body with critical signaling growth-factors which are scientifically proven to turn on stem cells in the bone, supporting the body’s ability to grow new healthy bone tissue, providing the key surface for calcium and minerals to bind.
In joint, nutrients such as glucosamine and chondroitin are building blocks for cartilage but still, need the right cells to put them together. Cyplexinol® provides the growth-factor signals which the body needs to start the cellular machinery to use those building blocks and produce new healthy cartilage tissue.
While supporting the body’s ability to grow new cartilage, these signaling growth-factors are functionally involved in modulating key cytokines so the body can fight inflammation, resulting in rapid joint comfort in as fast as seven days.
Solutions that Offer Fitness Goals
ZyCal Bioceuticals not only sells Cyplexinol® under the brand name Ostinol®, it licenses Cyplexinol® to other supplement companies, both within the USA and pharmaceuticals outside the country, providing technical, scientific, and clinical support to healthcare professionals, licensing companies, and consumers alike.
ZyCal constantly conducts clinical trials and pre-clinical research, providing the industry with cutting-edge research and information on stem-cell activations and tissue regeneration. ZyCal’s mission is to be at the forefront of bone and joint health to provide the best guidance and support to our healthcare professionals’ customers and consumers for outstanding bone and joint health.
Adoption of the Digital Media
Mr Scaffidi believes that digital media has been a remarkable transformation for the nutritional supplement industry. It has allowed small companies to get their message out to healthcare professionals and consumers alike, providing a level playing field compared to larger companies and even the pharmaceutical industry.
A Note of Advice
When asked to give a piece of advice to the budding enthusiast, Mr Scaffidi states, “The industry is large and proliferating as today’s consumers are looking for better, more unique nutrition for specific health support. Look at the data, see where you could provide a difference, and capitalize on that difference; don’t just provide another “me-too” product or a re-mixing of past ingredients.”
Embracing the Future Roadmap
Mr Scaffidi shared that ZyCal Bioceuticals is growing with expansion in its NJ manufacturing facility and a new, larger corporate headquarters in the greater Boston area of MA. ZyCal had committed significant resources to two major clinical trials with a Contract Research Organization (CRO).
He further states, “these trials and additional pre-clinical work will propel ZyCal to greater heights, strengthening our position as innovators and leaders in the natural bone and joint area.”
Additionally, ZyCal is exploring emerging research now in the scientific literature regarding how the same growth-factors within the Cyplexinol® complex are being studied as breakthroughs for medical conditions including osteoporosis, arthritis, sarcopenia, iron metabolism as well as ocular health, and nerve health., This research my help propel Cyplexinol® as a breakthrough platform technology for multiple health areas requiring tissue regeneration support.
